Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Melanoma 18Neoplasm Metastasis 14Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Recurrence 9Ovarian Neoplasms 7Skin Neoplasms 6Head and Neck Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma, Renal Cell 5Carcinoma, Basal Cell 5Triple Negative Breast Neoplasms 4Fallopian Tube Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Stomach Neoplasms 3Prostatic Neoplasms 3Multiple Myeloma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Merkel Cell 3Adenocarcinoma 3Sarcoma 2Pancreatic Neoplasms 2Lymphoma 2Lung Neoplasms 2Glioma 2

Interventions

Gemcitabine 22Fluorouracil 14Oxaliplatin 13Capecitabine 13Paclitaxel 12pembrolizumab 11Cisplatin 11Carboplatin 11Pemetrexed 10Leucovorin 9130-nm albumin-bound paclitaxel 9Ramucirumab 8zolbetuximab 7Albumin-Bound Paclitaxel 7trastuzumab deruxtecan 6Drug Therapy 5Docetaxel 5Bevacizumab 5Nivolumab 4Irinotecan 4vandetanib 3cemiplimab 3Everolimus 3EC145 3tislelizumab 2technetium 99m etarfolatide 2spartalizumab 2pralsetinib 2osimertinib 2nimotuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma × cemiplimab × Clear all
NCT05208944 2026-05-13

THIO Sequenced With Cemiplimab in Advanced NSCLC

Maia Biotechnology

Phase 2 Active not recruiting
227 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Maia Biotechnology

Phase 3 Recruiting
300 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT04646005 2025-09-08

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Regeneron Pharmaceuticals

Phase 2 Completed
113 enrolled 18 charts
Gynecologic

Adenocarcinoma, Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡